Author:
Van Cutsem Eric,di Bartolomeo Maria,Smyth Elizabeth,Chau Ian,Park Haeseong,Siena Salvatore,Lonardi Sara,Wainberg Zev A,Ajani Jaffer,Chao Joseph,Janjigian Yelena,Qin Amy,Singh Jasmeet,Barlaskar Ferdous,Kawaguchi Yoshinori,Ku Geoffrey
Reference29 articles.
1. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer;Van Cutsem;Gastric Cancer,2015
2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
3. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study;Janjigian;Proc Am Soc Clin Oncol,2021
4. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study;Thuss-Patience;Lancet Oncol,2017
5. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study;Satoh;J Clin Oncol,2014
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献